



NewTherapiesSubgroup

Agenda

July 19th 2016 12.30 pm – 2.30 pm

Central Manchester Trust, Pharmacy Dept.
Inpatient pharmacy meeting room.



Declarations of Interest (new declarations only)

Apologies

Item	Supporting papers enclosed
1) Minutes March Meeting	Item 1
2) Matters arising	Item 2 (none – all on agenda)
2a) Ulipristal intermittent use recommendation & pathway (updated)	Item 2a NTS final draft recommendation
2b) Ticagrelor for MI (license extension)	Item 2b NTS draft recommendation
2c) Lesinurad (Zurampic®) for the treatment of Gout	Item 2c NTS draft recommendation
2d) Brivaracetam (Briviact®) for epilepsy	Item 2d draft recommendation and specialist feedback.
2e) Safinamide (now launched)	Item 2e initial NTS review document MTRAC summary review (includes price)
3) Pregabalin/Gabapentin for chronic cough (unlicensed indication)	Item 3 NTS review document
4) Birch Bark extract wound therapy	Item 4 RDTC review document
5) Colchicine for pericarditis (unlicensed indication)	Item 5 NTS review document
6) Horizon Scanning documents and work plan	Item 6 horizon scanning

<p><i>New drugs/applications for consideration:</i></p> <ul style="list-style-type: none"> • Enstillar application from specialist (attached) • Feraccru® (<i>ferric maltol – indicated for the treatment of iron deficiency anaemia in adult patients with IBD</i>) 	<p>document</p> <p>Current Work plan</p>
<p>7) Updates from other groups</p>	<p>Verbal</p>
<p>a) GMMMG</p>	
<p>b) Interface Prescribing</p>	
<p>c) Formulary Subgroup</p>	
<p>8) AOB</p>	
<p>9) Date of Next Meeting: September 20th 2016 12.30-2.30pm,CMFT</p>	